Expertise in
3
conditions

Dr. Pearl C. Kwong

Dermatology
10175 Fortune Pkwy, Unit 1203, 
Jacksonville, FL 
Accepting New Patients
Offers Telehealth
Expertise in
3
conditions
10175 Fortune Pkwy, Unit 1203, 
Jacksonville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Pearl Kwong is a Dermatologist in Jacksonville, Florida. Dr. Kwong is highly rated in 3 conditions, according to our data. Her top areas of expertise are Molluscum Contagiosum, Impetigo, Acne, and Acute Febrile Neutrophilic Dermatosis. Dr. Kwong is currently accepting new patients.

Her clinical research consists of co-authoring 21 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in FL
Languages Spoken
English
Filipino
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

SUNCOAST SKIN SOLUTIONS
10175 Fortune Pkwy, Unit 1203, Jacksonville, FL 32256

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 11, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)
A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: November 27, 2024
Intervention Type: Combination product
Study Phase: Phase 2
A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa
A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2024
Intervention Type: Biological
Study Drug: FCX-007 (Dabocemagene Autoficel)
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Combination product
Study Phase: Phase 3
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

21 Total Publications

INDIVIDUAL ARTICLE: Appraisal of Ruxolitinib 1.5% Cream as a First-Line Topical Therapeutic Agent for Adolescents and Adults With Mild-to-Moderate Atopic Dermatitis.
INDIVIDUAL ARTICLE: Appraisal of Ruxolitinib 1.5% Cream as a First-Line Topical Therapeutic Agent for Adolescents and Adults With Mild-to-Moderate Atopic Dermatitis.
Journal: Journal of drugs in dermatology : JDD
Published: February 06, 2025
Similar Doctors
Expertise in
33
conditions
Dr. George J. Schmieder
Dermatology
Expertise in
33
conditions
Dr. George J. Schmieder
Dermatology

Park Avenue Dermatology PA

906 Park Ave, 
Orange Park, FL 
 (9.2 mi)
904-541-0315
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

George Schmieder is a Dermatologist in Orange Park, Florida. Dr. Schmieder is highly rated in 33 conditions, according to our data. His top areas of expertise are Actinic Keratosis, Psoriasis, Plaque Psoriasis, and Squamous Cell Skin Carcinoma. Dr. Schmieder is currently accepting new patients.

Expertise in
5
conditions
Dr. Ashley S. Wysong
Dermatology
Expertise in
5
conditions
Dr. Ashley S. Wysong
Dermatology
4500 San Pablo Rd S, 
Jacksonville, FL 
 (8.4 mi)
Experience:
16+ years
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients

Ashley Wysong is a Dermatologist in Jacksonville, Florida. Dr. Wysong has been practicing medicine for over 16 years is highly rated in 5 conditions, according to our data. Her top areas of expertise are Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Melanoma, and Keloids. Dr. Wysong is currently accepting new patients.

Expertise in
17
conditions
Dr. Jason C. Sluzevich
Dermatology
Expertise in
17
conditions
Dr. Jason C. Sluzevich
Dermatology

Mayo Clinic Jacksonville

4500 San Pablo Rd S, 
Jacksonville, FL 
 (8.4 mi)
904-953-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Sluzevich is a Dermatologist in Jacksonville, Florida. Dr. Sluzevich is highly rated in 17 conditions, according to our data. His top areas of expertise are Mycosis Fungoides, Acquired Ichthyosis, Cutaneous T-Cell Lymphoma (CTCL), and T-Cell Lymphoma. Dr. Sluzevich is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kwong's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile